$OGN

Drinane Juliana Papa sold $200K of OGN

Drinane Juliana Papa (Head of Mfg & Supply) sold 14,761 shares of Organon & Co. (OGN) at $13.57 ($0.20M total) on 2026-08-05.

Original reporting
SEC EDGAR · Drinane Juliana Papa
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OGN
Neutral
medium confidence
Mentioned
$OGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OGNNeutralLow
01

Why it matters

The filing discloses the sale size, price, and post-transaction holdings, but provides no new operational or financial information about OGN.

02

Market read

Traders may monitor for patterns in insider activity, but this single sale is unlikely to drive a fundamental repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the filing does not establish intent or future guidance changes.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-05

Background

SEC Form 4 reports an insider transaction for Organon & Co. (OGN) by Drinane Juliana Papa, Head of Mfg & Supply.

Company-level read

Ticker impact

$OGNNeutralMedium confidence
Context

Organon & Co. insider Drinane Juliana Papa sold 14,761 shares on 2026-08-05 at $13.57/share, totaling about $200.3K.

Expected impact

Likely limited near-term impact; treat as sentiment noise unless follow-on selling accelerates.

Evidence & confidence

Form 4 provides a disclosed transaction size and role, but it does not include new company fundamentals, guidance, or regulatory/operational developments.

Market effects

No direct sector read-through; insider sales are company-specific and often non-informational.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • Organon & Co.

    OGN, the company whose insider transaction is reported on Form 4.

  • Drinane Juliana Papa

    Officer (Head of Mfg & Supply) who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMGNMedAI 8/10

New Data Reshape Nonstatin Lipid Therapy Choices

Kelsey Norman, PharmD, discussed new data and guidelines reshaping hyperlipidemia management at the NEIAP 2026 Annual Forum. She highlighted the role of pharmacists in optimizing lipid-lowering therapies, including PCSK9 inhibitors, ezetimibe, and bempedoic acid. Norman noted the FDA's expanded indication for evolocumab (Repatha; Amgen) based on the VESALIUS-CV trial, and the missed primary endpoint in the Lp(a)HORIZON trial (NCT04023552) for pelacarsen (Novartis).

$OGNMedAI 8/10

Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years

Organon (OGN) announced FDA acceptance of a supplemental New Drug Application for MIUDELLA, seeking to extend its use from 3 to 6 years. The FDA decision is expected in Q2 2027. MIUDELLA is currently approved for 3-year use and is anticipated to launch commercially in late 2026. Clinical trials showed 99% contraceptive effectiveness. Organon licensed MIUDELLA from Sebela Women's Health in June 2026.